RNA splicing as a biomarker and phenotypic driver of meningioma DNA-methylation groups.

ABSTRACT:

Background

Advances in our understanding of the molecular biology of meningiomas have led to significant gains in the ability to predict patient prognosis and tumor recurrence and to identify novel targets for therapeutic design. Specifically, classification of meningiomas based on DNA methylation has greatly improved our ability to risk stratify patients, however new questions have arisen in terms of the underlying impact these DNA-methylation signatures have on meningioma biology.

Methods

This study utilizes RNA-sequencing data from 486 meningioma samples corresponding to 3 meningioma DNA-methylation groups (merlin-intact, immune-enriched, and hypermitotic), followed by in vitro experiments utilizing human meningioma cell lines.

Results

We identify alterations in RN

SUBMITTER: Leclair NK 

PROVIDER: S-EPMC11630566 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature